Phase I Trial of Intra-arterial Administration of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Patients with Multiple System Atrophy

<div>Study flow diagram. (a) Nine patients with multiple system atrophy-cerebellar type were enrolled in the present study. A three-stage dose escalation scheme was applied to determine the maximum tolerated dose of BM-MSCs. (b) According to the protocols of the clinical trial, patients visited the clinic seven times (V1–V7) to assess the safety and tolerability of intra-arterial administration of BM-MSCs. To explore the clinical efficacy, additional clinic visits were made 3 months after the intra-arterial administration (V8). Abbreviations: UMSARS: Unified Multiple System Atrophy Rating Scale; BME: bone marrow extraction; MSC: mesenchymal stem cell; BM-MSC: bone marrow-derived mesenchymal stem cell.</div>

Stem Cells International

fig1

Figure 1

Figure 1: Phase I Trial of Intra-arterial Administration of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Patients with Multiple System Atrophy 

Figure 1 | Phase I Trial of Intra-arterial Administration of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Patients with Multiple System Atrophy 